Drug‐Induced Liver Injury During Treatment With Tocilizumab: A Case Report of an Atypical Pattern Lesion
Pharmacology Research & Perspectives · 2026
DOI: 10.1002/prp2.70323 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pharmacology Research & Perspectives, 2026. Verfasst von Louis-Edmond Barbaro und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Université Côte d'Azur, University Hospital Centre of Nice, Nice, France. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Tocilizumab is an interleukin‐6 (IL‐6) receptor antagonist indicated for various rheumatologic conditions. While hepatotoxicity is a recognized adverse effect, it predominantly manifests as hepatocellular injury. We report a rare case of drug‐induced liver injury (DILI) presenting with a cholestatic pattern and cholangitis features in a 75‐year‐old patient treated for giant cell arteritis. Following the third tocilizumab infusion, the patient developed jaundice and abdominal pain. Laboratory investigations revealed a cholestatic pattern of liver injury (ALT/ALP ( R ) ratio ≤ 2) with marked cholestasis. Imaging findings raised suspicion for cholangitis. After ruling out infectious, autoimmune, and metabolic aetiologies, a liver biopsy confirmed neutrophilic cholangitis and marked intrahepatic and sinusoidal cholestasis. Drug discontinuation, along with ursodeoxycholic acid treatment, led to clinical and biochemical resolution. This case is notable as tocilizumab‐induced liver injury rarely presents with cholangitic features. The pathophysiology may involve the disruption of IL‐6 signaling, which plays a pivotal role in maintaining biliary epithelial integrity. Clinicians should be vigilant for this atypical cholestatic presentation to ensure prompt drug withdrawal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Université Côte d'Azur, University Hospital Centre of Nice, Nice, France.
- Department of Gastro-Enterology, Université Côte d'Azur, University Hospital Centre of Nice, Nice, France.
- Department of Rheumatology, Université Côte d'Azur, University Hospital Centre of Nice, Nice, France.
ORCID-Profile: Louis-Edmond Barbaro, Nouha Ben Othman, Delphine Viard, Elliot Ewig, Alexandre O Gérard
Zitieren
APA
Barbaro, L. E., Ben Othman, N., Viard, D., Rocher, F., Ewig, E., Mroue, R., Amigues, C., & Gérard, A. O. (2026). Drug‐Induced Liver Injury During Treatment With Tocilizumab: A Case Report of an Atypical Pattern Lesion. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70323
Vancouver
Barbaro LE, Ben Othman N, Viard D, Rocher F, Ewig E, Mroue R, et al. Drug‐Induced Liver Injury During Treatment With Tocilizumab: A Case Report of an Atypical Pattern Lesion. Pharmacology Research & Perspectives. 2026. doi:10.1002/prp2.70323
BibTeX
@article{Barbaro2026,
author = {Barbaro, Louis-Edmond and Ben Othman, Nouha and Viard, Delphine and Rocher, Fanny and Ewig, Elliot and Mroue, Raja and Amigues, Claire and Gérard, Alexandre O},
title = {Drug‐Induced Liver Injury During Treatment With Tocilizumab: A Case Report of an Atypical Pattern Lesion},
journal = {Pharmacology Research & Perspectives},
year = {2026},
doi = {10.1002/prp2.70323}
}
EUVIMED